News Novo Nordisk beefs up in oral obesity drugs with Vivtex deal Novo Nordisk is leaving no stone unturned in its bid to maintain its position in weight-loss therapies as it signs a $2.1bn alliance with Vivtex.
News GSK grows pipeline with 35Pharma takeover, Frontier deal GSK CEO Luke Miels signs a pair of pipeline-expanding deals, and the first acquisition on his watch, as the group prepares for a looming patent cliff.
News Astellas bets on Vir cancer drug, and other licensing deals Our latest round-up of pharma licensing deals features assets from Vir Biotech, Harbour BioMed, Unnatural Products, Genhouse, and CSL.
News Madrigal builds in MASH with $4.4bn+ Ribo alliance Already sitting on a blockbuster therapy for MASH, Madrigal has beefed up its pipeline with six siRNA candidates licensed from China's Ribo.
News AZ deepens Chinese ties, signs $18.5bn CSPC obesity deal AstraZeneca deepens ties with China, pledging $15bn in investment and signing a big $18.5bn alliance with CSPC Pharma for obesity and diabetes drugs.
News Boehringer signs €1bn+ deal for Simcere IBD candidate Boehringer Ingelheim has sourced an IL-23p19xTL1A bispecific antibody for inflammatory bowel disease, from China's Simcere, for €42m upfront.
News White House drops Heidi Overton pick for FDA chief At the eleventh hour, the White House has rescinded its nomination of Heidi Overton – a staunch Trump ally – to be FDA Commissioner.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.